search button
Open Access

Real‑world retrospective study of early‑stage prostate cancer at a Portuguese Comprehensive Cancer Centre: The PEarlC study

  • Authors:
    • Isaac Braga
    • Salomé Gonçalves‑Monteiro
    • Rita Calisto
    • Marta Rangel
    • Eduardo Medeiros
    • José Luís Cunha
    • Alina Rosinha
    • Ângelo Oliveira
    • Ana Cristina Fialho
    • Susana Santos
    • Patrícia Redondo
    • Maria José Bento

  • View Affiliations

  • Published online on: June 7, 2024     https://doi.org/10.3892/ol.2024.14495
  • Article Number: 362

  • Copyright: © Braga et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Despite the high prevalence of localised prostate cancer (LPC) and locally advanced prostate cancer (LAPC), evidence on the characteristics of patients, treatments and clinical outcomes stratified by disease risk is limited. The PEarlC study was conducted to characterise a cohort of patients with early‑stage prostate cancer that included real‑world clinical outcomes. Retrospective data from a cohort of patients diagnosed with LPC/LAPC between 2015 and 2017 and followed up until December 2020 at a Portuguese comprehensive cancer centre (IPO Porto) was analysed. Patients were classified as LPC (high‑ or non‑high‑risk) or LAPC according to European Association of Urology guidelines, were eligible if diagnosed at stage I‑III and followed up in Urology, Medical Oncology or Radiation Oncology outpatient clinics of IPO Porto. Data was collected from the medical/administrative records database. Clinical outcomes included prostate‑specific antigen (PSA) progression‑free survival, metastasis‑free survival, disease‑free survival, progression‑free survival, overall survival (OS), PSA response (palliative) and no evidence of residual tumour (prostatectomy). Time‑to‑event outcomes were compared between subgroups using the log‑rank test. A total of 790 patients were included (54.8% non‑high‑risk LPC, 30.9% high‑risk LPC, 14.3% LAPC) and the median follow‑up was 46.7 months. Patients had a median age of 68.0 years. The majority of patients were stage II (52.9%) and Eastern Cooperative Oncology Group 0‑1 (99.9%) and received treatment with curative intent (85.4%). The median was only achieved in progression‑free survival (29.9 months; 95% CI, 26.5‑41.0 months), as evaluated in palliative patients. At year 5, 82.9% were free of PSA progression (curative), 87.5% were metastasis‑free, 83.7% were disease‑free, all patients in palliative treatment progressed and the 5‑year OS rate was 92.9% (CI 95%, 90.2‑95.7%). Among patients with LPC, OS was worse in high‑risk vs. non‑high‑risk patients (5‑year OS rate, 88.8% vs. 96.8%; hazard ratio=3.34, CI 95%, 1.64‑7.05; P=0.001). PSA response rate was 81.4% in the palliative setting. There was no evidence of residual tumour in 61.6% of patients who underwent prostatectomy. Although most patients with early‑stage prostate cancer treated at IPO Porto showed positive 5‑year real‑world outcomes, patients with high‑risk LPC showed worse OS compared with patients with non‑high‑risk LPC and therefore a poorer prognosis. The present large‑sample real‑world study is an important contribution to reducing the evidence gap on prostate cancer.
View Figures
View References

Related Articles

Journal Cover

August-2024
Volume 28 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 5.7
  • CiteScore Rank: Q2: #139/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.574
  • SCImago Journal Rank (SJR): 0.644
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Braga I, Gonçalves‑Monteiro S, Calisto R, Rangel M, Medeiros E, Cunha JL, Rosinha A, Oliveira Â, Fialho AC, Santos S, Santos S, et al: Real‑world retrospective study of early‑stage prostate cancer at a Portuguese Comprehensive Cancer Centre: The PEarlC study. Oncol Lett 28: 362, 2024
APA
Braga, I., Gonçalves‑Monteiro, S., Calisto, R., Rangel, M., Medeiros, E., Cunha, J.L. ... Bento, M.J. (2024). Real‑world retrospective study of early‑stage prostate cancer at a Portuguese Comprehensive Cancer Centre: The PEarlC study. Oncology Letters, 28, 362. https://doi.org/10.3892/ol.2024.14495
MLA
Braga, I., Gonçalves‑Monteiro, S., Calisto, R., Rangel, M., Medeiros, E., Cunha, J. L., Rosinha, A., Oliveira, Â., Fialho, A. C., Santos, S., Redondo, P., Bento, M. J."Real‑world retrospective study of early‑stage prostate cancer at a Portuguese Comprehensive Cancer Centre: The PEarlC study". Oncology Letters 28.2 (2024): 362.
Chicago
Braga, I., Gonçalves‑Monteiro, S., Calisto, R., Rangel, M., Medeiros, E., Cunha, J. L., Rosinha, A., Oliveira, Â., Fialho, A. C., Santos, S., Redondo, P., Bento, M. J."Real‑world retrospective study of early‑stage prostate cancer at a Portuguese Comprehensive Cancer Centre: The PEarlC study". Oncology Letters 28, no. 2 (2024): 362. https://doi.org/10.3892/ol.2024.14495